| 标题 |
[高分] Liraglutide (SAXENDA) in obesity in adolescents
利拉鲁肽治疗青少年肥胖症
|
| 网址 | |
| DOI |
暂未提供，该求助的时间将会延长，查看原因？
|
| 其它 |
作者：D Gunthert 摘要：This marketing authorisation was based on a single trial of liraglutide versus placebo that did not show a reduction in the clinical complications associated with obesity in adolescents. After 56 weeks of treatment, body mass index in the liraglutide group was about 1.6 kg/m~2 lower than in the placebo group, corresponding to a mean difference in body weight of 5 kg. 26 weeks after stopping treatment, the effect of liraglutide had receded. Liraglutide can cause gastrointestinal adverse effects (especially vomiting) and hypoglycaemia in adolescents, and exposes them to some poorly defined risks such as cancer, and possibly suicidal ideation and suicide. Avoiding the use of liraglutide in adolescents is called for, based on these disproportionate adverse effects. 年份：2022 |
| 求助人 | |
| 下载 |
云凡
yx_cheng
pcr163
Emma
coolkid
诸葛带你做分析_yorfir
科目三
SYLH
我的文献呢
耀星光
Sandy
赘婿
可爱打工霖
852
轻舟
可爱的函函
汉堡包
小虎
搜集达人
英俊的铭
皖公网安备34019202002308
